Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways

Key Points

• To identify predictive biomarkers associated with secukinumab response in psoriatic arthritis through transcriptomic profiling.
• Performed transcriptomic profiling before and after secukinumab treatment.
• Used weighted gene co-expression network analysis (WGCNA) to identify additional genes.
• Analyzed the involvement of identified genes in metabolic pathways.
• Two genes were identified as pre-treatment predictive biomarkers of secukinumab response.
• Five additional candidate genes were found through WGCNA.
• The identified genes are linked to metabolic pathways that may influence treatment response.